|
| References
- Heart,
circulation, and the effects of testosterone. |
6.
Shepherd J. Danazol and plasma lipoprotein metabolism.
[Review] [17 refs]. International Journal of Gynaecology
& Obstetrics 1995;50 Suppl 1:S23-S26
Abstract: The potential long-term impact of danazol on
coronary risk hinges on its effect on lipoprotein metabolism
rather than its influence on total plasma lipids. Danazol may
exert a regulatory influence on three key processes in lipoprotein
metabolism: hepatic lipase activity; low-density lipoprotein
receptor function; and lecithin:cholesterol acyl-transferase
activity. Danazol decreases plasma fibrinogen and lipoprotein
(a) levels, promotes fibrinolysis and causes a rise in plasminogen.
Such changes are beneficial as they inhibit the process of thrombosis.
Androgenic properties of danazol produce effects of plasma lipids
and lipoproteins which oppose estrogen-induced changes. The
usual recipients of danazol therapy are premenopausal females,
in whom the absolute risk of ischemic heart disease is low.
If the drug were shown to increase ischemic heart disease risk,
detrimental factors must be weighted against its considerable
and proven clinical benefits. [References: 17]
Notes: Interesting article because it suggests that the
increase in free biologically active testosterone produced by
danazol has a beneficial effect on several blood coagulation
and lipid factors.
|
| back
to reference list - heart |
| back
to reference library menu |
|
